



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

BIB DATA SHEET

CONFIRMATION NO. 1234

SERIAL NUMBER 10/550,358	FILING or 371(c) DATE 09/23/2005 RULE	CLASS 514	GROUP ART UNIT 1617	ATTORNEY DOCKET NO. PD/4-32802A		
APPLICANTS Maximilian Grassberger, Wien, AUSTRIA; Stefan Hirsch, Lorrach, GERMANY; Friedrich Karl Mayer, Oberwil, SWITZERLAND; Josef Gottfried Meingassner, Perchtoldsdorf, AUSTRIA; Carle Paul, Mulhouse, FRANCE; Nabila Sekkat, Basel, SWITZERLAND; Anton Stutz, Wien, AUSTRIA; ** CONTINUING DATA ***** This application is a 371 of PCT/EP04/03511 04/02/2004 ** FOREIGN APPLICATIONS ***** UNITED KINGDOM 0307864.9 04/04/2003 ** IF REQUIRED, FOREIGN FILING LICENSE GRANTED ** 02/02/2006						
Foreign Priority claimed <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	35 USC 119(a-d) conditions met <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Met after Allowance	STATE OR COUNTRY AUSTRIA	SHEETS DRAWINGS 0	TOTAL CLAIMS 6	INDEPENDENT CLAIMS 2
Verified and Acknowledged	/RICHARD A HOUGHTLING/ Examiner's Signature	Initials				
ADDRESS NOVARTIS CORPORATE INTELLECTUAL PROPERTY ONE HEALTH PLAZA 104/3 EAST HANOVER, NJ 07936-1080 UNITED STATES						
TITLE Synergistic combinations of macrolide t-cell modulator or immunosuppressant and a retinoid						
FILING FEE RECEIVED 1030	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:		<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees (Filing) <input type="checkbox"/> 1.17 Fees (Processing Ext. of time) <input type="checkbox"/> 1.18 Fees (Issue) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit			